A Large Single Center’s Clinical Experience with Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis and a Baseline FEV1 of Less Than 40 Percent Predicted
{"title":"A Large Single Center’s Clinical Experience with Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis and a Baseline FEV1 of Less Than 40 Percent Predicted","authors":"R. Kapolka, W. Hunt","doi":"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2025","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":411070,"journal":{"name":"TP32. TP032 EPIDEMIOLOGY, BIOMARKERS, AND THERAPY IN CF AND NON-CF BRONCHIECTASIS","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP32. TP032 EPIDEMIOLOGY, BIOMARKERS, AND THERAPY IN CF AND NON-CF BRONCHIECTASIS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}